全文获取类型
收费全文 | 98858篇 |
免费 | 7036篇 |
国内免费 | 2483篇 |
专业分类
耳鼻咽喉 | 436篇 |
儿科学 | 2226篇 |
妇产科学 | 1055篇 |
基础医学 | 6129篇 |
口腔科学 | 339篇 |
临床医学 | 14793篇 |
内科学 | 28378篇 |
皮肤病学 | 175篇 |
神经病学 | 3734篇 |
特种医学 | 6806篇 |
外国民族医学 | 10篇 |
外科学 | 11159篇 |
综合类 | 17380篇 |
现状与发展 | 5篇 |
预防医学 | 3635篇 |
眼科学 | 516篇 |
药学 | 7141篇 |
72篇 | |
中国医学 | 2872篇 |
肿瘤学 | 1516篇 |
出版年
2024年 | 89篇 |
2023年 | 1509篇 |
2022年 | 2077篇 |
2021年 | 3831篇 |
2020年 | 3970篇 |
2019年 | 3475篇 |
2018年 | 3446篇 |
2017年 | 3406篇 |
2016年 | 3534篇 |
2015年 | 3645篇 |
2014年 | 7132篇 |
2013年 | 7157篇 |
2012年 | 6071篇 |
2011年 | 6405篇 |
2010年 | 5341篇 |
2009年 | 5014篇 |
2008年 | 4954篇 |
2007年 | 4971篇 |
2006年 | 4553篇 |
2005年 | 3855篇 |
2004年 | 3150篇 |
2003年 | 2694篇 |
2002年 | 2234篇 |
2001年 | 2068篇 |
2000年 | 1616篇 |
1999年 | 1416篇 |
1998年 | 1255篇 |
1997年 | 1151篇 |
1996年 | 938篇 |
1995年 | 984篇 |
1994年 | 883篇 |
1993年 | 750篇 |
1992年 | 688篇 |
1991年 | 552篇 |
1990年 | 475篇 |
1989年 | 418篇 |
1988年 | 389篇 |
1987年 | 333篇 |
1986年 | 282篇 |
1985年 | 346篇 |
1984年 | 275篇 |
1983年 | 151篇 |
1982年 | 200篇 |
1981年 | 159篇 |
1980年 | 133篇 |
1979年 | 110篇 |
1978年 | 88篇 |
1977年 | 59篇 |
1976年 | 57篇 |
1975年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
12.
目的 建立妊娠11~13+6周子宫动脉多普勒参数在低危人群中的正常参考值,同时评估其对不良妊娠结局的预测价值。方法 收集2019年6月至2021年6月于我院行产前超声检查的妊娠11~13+6周孕妇,根据妊娠结局分组。收集两侧子宫动脉多普勒指标,包括搏动指数(PI)、阻力指数(RI)、舒张早期是否有切迹,以及孕妇基本临床资料和胎儿出生信息,将以上相关参数进行统计学分析。结果 最终纳入800例孕妇,包括正常妊娠结局组740例和不良妊娠结局组60例。两组孕妇体质量指数(BMI)、分娩孕周和胎儿出生体质量比较,差异均有统计学意义(均P<0.05)。随着孕周的增加,子宫动脉两侧平均搏动指数(mPI)、平均阻力指数(mRI)和两侧舒张早期切迹检出率均呈逐渐下降的趋势。ROC曲线分析显示,mPI、mRI及两侧舒张早期切迹预测妊娠结局的曲线下面积(AUC)分别为0.542、0.574、0.521,三者联合预测妊娠结局的AUC为0.648;孕妇BMI、年龄mPI、mRI及两侧舒张早期切迹预测妊娠结局的AUC为0.751。结论 建立了低危人群在妊娠11~13+6周子宫动脉多普勒参数的正常参考值范围。在妊娠11~13+6周单纯应用子宫动脉多普勒参数预测妊娠结局的价值有限,将子宫动脉参数与临床相关指标结合可提高对不良妊娠结局的预测价值。 相似文献
13.
《介入医学杂志(英文)》2022,5(4):196-199
ObjectiveThis study aimed to analyze and evaluate the results of mid-term follow-up after fetal pulmonary valvuloplasty (FPV) in fetuses with pulmonary atresia with intact ventricular septum (PA/IVS).MethodsFrom August 31, 2018, to May 31, 2019, seven fetuses with PA/IVS and hypoplastic right heart were included in this study. All underwent echocardiography by the same specialist and were operated on by the same team. Intervention and echocardiography data were collected, and changes in the associated indices noted during follow-up were analyzed.ResultsAll seven fetuses successfully underwent FPV. The median gestational age at FPV was 27.54 weeks. The average FPV procedural time was 6 ?min. Persistent bradycardia requiring treatment occurred in 4/7 procedures. Finally, five pregnancies were successfully delivered, and the other two were aborted. Compared to data before fetal cardiac interventions (FCI), tricuspid valve annulus diameter/mitral valve annulus diameter (TV/MV) and right ventricle diameter/left ventricle diameter (RV/LV) of all fetuses had progressively improved. The maximum tricuspid regurgitation velocity decreased from 4.60 ?m/s to 3.64 ?m/s. The average follow-up time was 30.40 ?± ?2.05 months. During the follow-up period, the diameter of the tricuspid valve ring in five children continued to improve, and the development rate of the tricuspid valve was relatively obvious from 6 months to 1 year after birth. However, the development of the right ventricle after birth was relatively slow. It was discovered that there were individual variations in the development of the right ventricle during follow-up.ConclusionThe findings support the potential for the development of the right ventricle and tricuspid valve in fetuses with PA/IVS who underwent FCI. Development of the right ventricle and tricuspid valve does not occur synchronously during pregnancy. The right ventricle develops rapidly in utero, but the development of tricuspid valve is more apparent after birth than in utero. 相似文献
14.
王志敏 《中国工业医学杂志》2022,35(5):463-465
[摘要]?目的?探讨GeneXpert MTB/RIF检测技术在肺结核诊断中的应用价值。方法?以2020年7月—2021年6月在天门市第一人民医院治疗的疑似肺结核患者107例作为研究对象,所有患者均留取痰标本,进行痰涂片、痰培养、GeneXpert MTB/RIF检测、比例法药敏试验。以培养法和比例法药敏结果为金标准,计算GeneXpert MTB/RIF检测结核分枝杆菌(Mycobacterium tuberculosis,MTB)及其对于利福平耐药性检测的灵敏度、特异度、与金标准的的一致率。结果?107例疑似肺结核患者中,痰涂片阳性39例(36.45%),涂片阴性68例(63.55%)。以痰培养结果为金标准,GeneXpert MTB/RIF检测TBM的灵敏度为85.42%(41/48),特异度为88.14%(52/59)。GeneXpert MTB/RIF与痰培养诊断一致率为86.92%(93/107);进一步分析,GeneXpert MTB/RIF检测痰涂片阳性患者MTB的灵敏度为97.22%(35/36),特异度为33.33%(1/3),检测涂片阴性患者MTB的灵敏度为50.00%(6/12),特异度为91.07%(51/56)。以比例法药敏结果为金标准,确认痰培养阳性36例患者中利福平耐药有4例(11.11%),敏感的有32例(88.89%);GeneXpert MTB/RIF检测痰培养阳性患者利福平耐药的灵敏度为75.00%(3/4),特异度为93.75%(30/32)。GeneXpert MTB/RIF与比例法药敏试验一致率为91.67%。结论?GeneXpert MTB/RIF检测技术对于肺结核诊断以及利福平的耐药分析具有重要实用价值,可以作为金标准。 相似文献
15.
Diabetic foot ulcer is a devastating complication of diabetes mellitus and significant cause of mortality and morbidity all over the world and can be complex and costly. The development of foot ulcer in a diabetic patient has been estimated to be 19%-34% through their lifetime. The pathophysiology of diabetic foot ulcer consist of neuropathy, trauma and, in many patients, additional peripheral arterial disease. In particular, diabetic neuropathy leads to foot deformity, callus formation, and insensitivity to trauma or pressure. The standard algorithms in diabetic foot ulcer management include assessing the ulcer grade classification, surgical debridement, dressing to facilitate wound healing, off-loading, vascular assessment (status and presence of a chance for interventional vascular correction), and infection and glycemic control. Although especially surgical procedures are sometimes inevitable, they are poor predictive factors for the prognosis of diabetic foot ulcer. Different novel treatment modalities such as nonsurgical debridement agents, oxygen therapies, and negative pressure wound therapy, topical drugs, cellular bioproducts, human growth factors, energy-based therapies, and systematic therapies have been available for patients with diabetic foot ulcer. However, it is uncertain whether they are effective in terms of promoting wound healing related with a limited number of randomized controlled trials. This review aims at evaluating diabetic foot ulcer with regard to all aspects. We will also focus on conventional and novel adjunctive therapy in diabetic foot management. 相似文献
16.
17.
目的 基于数据非依赖性采集的定量蛋白质组学技术(data independent acquisition,DIA)对稳定性冠心病血瘀证患者的血浆蛋白质进行研究分析,初步探索冠心病血瘀证的关键生物学过程与核心靶点。方法 选择中国中医科学院广安门医院心血管科收治的5例稳定性冠心病患者作为疾病观察组,同时选取健康成人5人作为对照组,采用DIA蛋白质组学技术对受试者的血浆进行检测,确定蛋白质表达量后进行差异蛋白质表达分析、GO富集分析、KEGG信号通路图查询和蛋白质互作网络分析。结果 在差异倍数为1.5倍时,疾病观察组相比于健康对照组,共鉴定到22个蛋白质下调,9个蛋白质上调。进一步的生物信息学分析表明,冠心病血瘀证的生物学过程与补体参与的慢性炎症反应有关,关键信号通路是补体与凝血级联反应的信号通路,核心蛋白质为C反应蛋白、转甲状腺素蛋白、补体因子H、维生素D结合蛋白等。结论 冠心病血瘀证的生物学过程与补体参与的慢性炎症反应有关。 相似文献
18.
19.
20.
《Archivos de bronconeumología》2022,58(1):11-21
BackgroundWe aimed to describe the effectiveness and safety of inhaled antibiotics in chronic obstructive pulmonary disease (COPD) patients, as well as the patient profile in which they are usually prescribed and the patient groups that can most benefit from this treatment.MethodsMulticentre retrospective observational cohort study in COPD patients who had received ≥1 dose of inhaled antibiotics in the last 5 years. Clinical data from the two years prior to and subsequent to the start of the treatment were compared. Primary outcome: COPD exacerbations. Secondary outcomes: side effects, symptomatology (sputum purulence, dyspnoea), microbiological profile and pathogen eradication.ResultsOf 693 COPD patients analyzed (aged 74.1; 86.3% men; mean FEV1 = 43.7%), 71.7% had bronchiectasis and 46.6% presented chronic bronchial infection (CBI) by Pseudomonas aeruginosa (PA). After 1 year of treatment with inhaled antibiotics, there was a significant decrease in the number of exacerbations (?33.3%; P < .001), hospital admissions (?33.3%; P < .001) and hospitalization days (?26.2%; P = .003). We found no difference in effectiveness between patients with or without associated bronchiectasis. Positive patient outcomes were more pronounced in PA-eradicated patients. We found a significant reduction in daily expectoration (?33.1%; P = .024), mucopurulent/purulent sputum (?53.9%; P < .001), isolation of any potentially pathogenic microorganisms (PPM) (?16.7%; P < .001), CBI by any PPM (?37.4%; P < .001) and CBI by PA (?49.8%; P < .001). CBI by any PPM and ≥three previous exacerbations were associated with a better treatment response. 25.4% of patients presented non-severe side-effects, the most frequent of these being bronchospasm (10.5%), dyspnoea (8.8%) and cough (1.7%).ConclusionsIn COPD patients with multiple exacerbations and/or CBI by any PPM (especially PA), inhaled antibiotics appear to be an effective and safe treatment, regardless of the presence of bronchiectasis. 相似文献